Robert Whitfield MDAmerica's Breast Implant Illness Expert™

BIA-ALCL Is a Lymphoma, Not Breast Gland Cancer

30 Sept 2026 · 1 min

Watch on YouTube

1:17

In this brief explanatory video, Dr. Robert Whitfield clarifies that breast‑implant‑associated anaplastic large‑cell lymphoma (BIA‑ALCL) is an uncommon T‑cell non‑Hodgkin lymphoma, not a carcinoma of the breast gland. He emphasizes that the malignancy originates in the scar tissue (capsule) surrounding the implant and in the peri‑implant fluid, not in breast tissue itself. Dr. Whitfield cites the OpenEvidence AI platform, NCCN guidelines, and pathology literature to support the definition of BIA‑ALCL as a disease of the implant capsule. The key message is the critical distinction between a lymphoma of immune cells and breast gland cancer, to avoid confusion among patients and clinicians.

Chapters

People hear breast implant and cancer in the same sentence and assume that it is a breast cancer, which it is not. So BIA-ALCL is an uncommon T-cell non-Hodgkin lymphoma. So in plain language, it is a cancer of the immune cells, not a cancer of the breast gland itself. So once again, this is not a breast cancer. It's not part of the breast gland. Itself. It's an important distinction. We don't ever want to confuse that. This is generated predominantly in the scar tissue of and around the implant. So per OpenEvidence, which is an AI platform that we can utilize as physicians to access literature, both that and drawing on the NCCN guidelines and pathology sources, it describes it as a disease of the implant capsule rather than the breast itself, as I mentioned previously. In most cases, it's found in the scar tissue and the fluid near the implant, not in the breast tissue itself. People hear breast implant and cancer in the same sentence and assume that it is breast cancer, which it is not. It is a lymphoma associated with the capsule and the fluid around some implants.